Peregrine Capital Management LLC Raises Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Peregrine Capital Management LLC boosted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 12.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 342,845 shares of the company's stock after buying an additional 36,958 shares during the period. Peregrine Capital Management LLC owned approximately 0.38% of Myriad Genetics worth $4,700,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new stake in Myriad Genetics in the 3rd quarter valued at $32,000. KBC Group NV lifted its holdings in shares of Myriad Genetics by 132.8% during the 4th quarter. KBC Group NV now owns 5,845 shares of the company's stock worth $80,000 after acquiring an additional 3,334 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock valued at $87,000 after purchasing an additional 583 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its stake in Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock valued at $132,000 after purchasing an additional 1,471 shares during the last quarter. Finally, Meeder Asset Management Inc. increased its position in Myriad Genetics by 588.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,922 shares of the company's stock valued at $135,000 after acquiring an additional 4,207 shares during the period. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Myriad Genetics Stock Performance

Shares of MYGN traded down $0.72 during trading hours on Friday, hitting $14.26. The company's stock had a trading volume of 472,852 shares, compared to its average volume of 1,075,111. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics, Inc. has a 52-week low of $12.04 and a 52-week high of $29.30. The business has a 50 day simple moving average of $13.46 and a two-hundred day simple moving average of $19.65. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -10.93 and a beta of 1.88.

Analyst Ratings Changes

Several equities analysts have issued reports on MYGN shares. Leerink Partnrs cut shares of Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research report on Monday, December 9th. StockNews.com lowered shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Thursday. The Goldman Sachs Group cut their target price on shares of Myriad Genetics from $29.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Bank of America dropped their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating on the stock in a research note on Friday, December 13th. Finally, Leerink Partners lowered shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $30.00 to $21.00 in a research note on Monday, December 9th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $22.54.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.